News

Earlier Biologics Use in JIA Allows Less Steroids : More remissions are not the new rule with aggressive therapy, but other markers show improvement.


 

However, Dr. Russo said he did not see any significant differences in clinical measures of disease activity, including inactive disease or remission, on or off medication.

“It was difficult to compare disability rates because in the two eras, we used different measures of disability,” he added.

“But it was my clinical impression that there was a tendency toward a lower percentage of disabled patients in the 2000s.”

Dr. Russo also did not look specifically at osteoporosis in the groups, but said “I have the feeling that we now see fewer patients with short stature than we did in the past.”

Pages

Recommended Reading

Methotrexate May Benefit Juvenile Scleroderma
MDedge Rheumatology
Low Vitamin D Levels in Rheum Clinic Patients
MDedge Rheumatology
Methotrexate-Related GI Upset Common in JIA
MDedge Rheumatology
Joint-Sparing Surgery Helps Ease Deformities
MDedge Rheumatology
Obesity at Age 18 Found to Increase PsA Risk
MDedge Rheumatology
Global Data: Cancer Very Rare in Children on Etanercept
MDedge Rheumatology
Tocilizumab Shows Efficacy for Systemic JIA : These data are proof of the principle that many patients seem to benefit from blocking IL-6.
MDedge Rheumatology
How to Deliver Bad News to Parents of Pediatric Patients
MDedge Rheumatology
Child's Fever, Limp May Be Septic Arthritis
MDedge Rheumatology
Lung Function Often Impaired in Juvenile Dermatomyositis
MDedge Rheumatology